China Resources announced the acquisition of well-known pharmaceutical company Boya Bio.

Pharma Network September 29 - The acquisition of Boya Bio by China Resources Pharmaceuticals is an important step in the field of blood products.
China Resources Pharma, the blood products giant september 28, China Resources Pharma released an inside information "on the proposed acquisition of the letter of intent": who whowed subsidiary China Resources Pharmaceuticals Holdings intends to acquire the target company Boya Bio's controlling stake, and the proposed acquisition of the terms of further negotiations between China Resources Pharmaceutical Holdings and Gotjia.
that Boya Bio is mainly engaged in the development, production and sale of blood products, diabetes drugs, anti-infected chemicals and biochemical drugs.
yesterday, Gautejia Group and China Resources Pharmaceutical Holdings signed the Investment Intent Agreement.
Gautejia Group transferred its share agreement of not less than 69,331,978 shares of listed companies (16% of the total number of shares of listed companies) to China Resources Pharmaceutical Holdings and entrusted voting rights to all remaining shares of listed companies to China Resources Pharmaceutical Holdings for exercise.
the above-mentioned matters are finally reached, it will lead to changes in the actual controller of the listed company.
In addition, with regard to the acquisition of the target company, China Resources Pharma and Gautejia Group recognize its value as a blood products platform, Andejia Group actively assists China Resources Pharmaceuticals to take control of the target company and achieve a smooth transition of the target company.
It is worth noting that the specific number of shares traded in this share transfer, transaction price, payment process and time node arrangements by the two sides to sign a separate "share transfer agreement" agreement, the "share transfer agreement" can eventually be signed there is uncertainty, and this share transfer needs to be approved by the competent state-owned department, but also through the Shenzhen Stock Exchange compliance confirmation before the Transfer of shares in the Shenzhen branch of China Securities Registration and Settlement Co., Ltd.
The difficulties to be solved, the central enterprise as the development, production and sale of blood products enterprises, Boya Bio has been with Hualan Biological, Shanghai Lais, Temple of Heaven biology and called China's four major blood products, but in recent years, the company's performance has declined, frequently.
2019, Boa Bio-Home's net profit was RMB426 million, down 9.17% YoY, with blood products as a share of revenue falling to 33.96% from 50.12% in 2017; In the first half of the year, Boa Bio's performance also continued to decline, with revenue of RMB1,328 million, down 3.47% YoY, and net profit of RMB161 million, down 24.42% YoY.
addition to the decline in performance, Boya Bio also faces the problem of Danxia project, which is also the focus of investors.
In 2017, Gauteja acquired a 99% stake in Danxia Bio, a blood products manufacturer that is also part of Boya Bio, and said it would use Boya Bio as the sole platform for blood products in the future, but the two have been slow to integrate for various reasons, forming a competitive relationship.
At the same time, In May 2017 and 2019, Boa Bio signed procurement contracts with Danxia Bio for plasma and other products, paying an advance payment of more than $800 million, citing "the full use of plasma resources to alleviate the shortage of blood products".
However, as early as April 2017, Danxia Bio was ordered to stop production due to excessive aluminum ions in human blood protein products, and the two transactions were not approved for plasma transfer, so as of August 2020, Boya Bio was unable to receive the plasma purchased at great cost.
Because it has not been able to receive orders, which has had an indirect impact on Boa Bio's performance, the company explained the sharp decline in cash flow in its 2019 annual report, mainly due to the purchase of raw materials, advance payment of Boa (Guangdong) (formerly "Danxia Bio") raw plasma purchases and the payment of market service fees.
combined with the above background, there is a view in the industry that, facing the dilemma of Danxia bio-plasma can not be shipped out, the transfer of Boa bio-control to the state-owned enterprises, or can help to deal with government relations more quickly, so as to solve the current situation. according to
data, China Resources Pharmaceutical Group Co., Ltd. is China Resources (Group) Co., Ltd. in accordance with the State Council SASAC "to build a central enterprise pharmaceutical platform" requirements, in the reorganization of the central enterprise Huayuan Group, 39 Group pharmaceutical resources on the basis of the establishment of large-scale pharmaceutical manufacturing and distribution enterprises, for China Resources Group to integrate the development of the domestic pharmaceutical industry who-owned enterprises.
Boya Bio, Gautejia and this Big Mac state-owned enterprises, or can use each other's advantages in government affairs to break through the difficult situation.
Expanded product portfolio, the 2019 annual report of China Resources Pharmaceuticals in the therapeutic field shows that its manufacturing business covers the research and development, production and sale of pharmaceutical products, the production of more than 540 kinds of drugs, the product portfolio includes chemicals, Chinese medicine, biologics and nutritional care products, covering a wide range of therapeutic areas, including cardiovascular, digestive and metabolic, high-volume intravenous fluids, pediatrics, respiratory systems, etc., without the relevant business description of blood products.
search of China Resources Pharmaceuticals' official website, it was found that as early as June 2018, China Resources Pharmaceuticals had discussed strategic cooperation with Jetblyn.
, Jetblyn is the world's largest producer of blood products, with a global network and the largest supplier of blood products in the domestic market.
JetBelin products - biologics for the treatment of neonatal clotting disorders, immunodeficiency, α-1 antitrinase deficiency, hereditary angioedema and hemolytic diseases, but also for heart and transplant surgery, wound healing and treatment of shock, burns and sepsis, are widely recognized by experts and patients.
the two sides will continue to further promote business cooperation, based on the domestic distribution market, as well as terminal coverage of a full range of strategic business cooperation.
to continuously strengthen the combined strength of both products, distribution business, and even market influence.
blood products, vaccine products, injections and other pharmaceutical refrigeration products, for China's pharmaceutical cold chain logistics of the main categories, and this is the advantages of China Resources Pharmaceuticals led by a number of pharmaceutical companies.
the acquisition of Boa Bio by China Resources Pharmaceuticals, or an important step in the field of blood products.
.